LivaNova recognizes final decision from US CMS for NCD of VNS Therapy for treatmentresistant depression

LivaNova recognizes final decision from US CMS for NCD of VNS Therapy for treatment-resistant depression

09:11 EST 19 Feb 2019 | Compelo Medical Devices

Per its final decision, CMS has modified the NCD for VNS Therapy for TRD to include feedback received during the comment period in a manner that aligns the

More From BioPortfolio on "LivaNova recognizes final decision from US CMS for NCD of VNS Therapy for treatment-resistant depression"